Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
2(50.0%)
4Total
Phase 2(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07559045Phase 2Recruiting

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Role: lead

NCT06412107Not ApplicableCompleted

Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors

Role: collaborator

NCT06725225Not ApplicableNot Yet Recruiting

Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients

Role: lead

NCT05901584Phase 2Unknown

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Role: lead

All 4 trials loaded